---
document_datetime: 2024-12-11 13:56:11
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/beovu-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: beovu-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 6.8288489
conversion_datetime: 2025-12-20 18:11:01.538081
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Beovu

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0031/G          | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - | 10/12/2024                          |                                             | Annex II and PL                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | Not including batch control/testing A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                               |            |            |                 |                                                                                                                                                                                                                                                                     |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0029             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                            | 17/10/2024 | 22/11/2024 | SmPC and PL     |                                                                                                                                                                                                                                                                     |
| R/0030              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                      | 25/07/2024 | 19/09/2024 | SmPC and PL     | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Beovu in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| II/0028             | Update of section 4.8 of the SmPC in order to add 'Scleritis' to the list of adverse drug reactions (ADRs) with frequency 'uncommon', following the recommendation by PRAC in the outcome for the signal assessment of Scleritis. The Package Leaflet is updated accordingly. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 11/07/2024 | 22/11/2024 | SmPC and PL     | For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                       |
| PSUSA/10829 /202310 | Periodic Safety Update EU Single assessment - brolucizumab                                                                                                                                                                                                                                                                                                                   | 16/05/2024 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                   |
| IAIN/0027/G         | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                                                                                                                                                     | 22/02/2024 | 19/09/2024 | Annex II and PL |                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|         | Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site A.7 - Administrative change - Deletion of manufacturing sites   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0025 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                           | 11/09/2023 | 19/09/2024 | Annex II    |                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0021 | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                      | 25/05/2023 | 29/06/2023 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0018 | Update of sections 4.2 and 5.1 of the SmPC in order to introduce an alternative loading posology regimen for wet AMD and update information based on modelling and simulation studies; the Package Leaflet is updated accordingly. The RMP version 11.0 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance          | 25/05/2023 | 29/06/2023 | SmPC and PL | In treatment initiation, alternative loading dose regimen is 6 mg brolucizumab (0.05 ml solution) administered every 6 weeks for the first 2 doses, with a disease activity assessment suggested 12 weeks (3 months) after treatment start. A third dose may be administered based on disease activity as assessed by visual acuity and/or anatomical parameters at week 12. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

| PSUSA/10829 /202210   | Periodic Safety Update EU Single assessment - brolucizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 12/05/2023   | n/a        |                 | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-------------------------------------|
| IAIN/0024/G           | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - | 11/04/2023   | 29/06/2023 | Annex II and PL |                                     |
| IB/0023               | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 20/02/2023   | n/a        |                 |                                     |
| IB/0020               | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 19/12/2022   | n/a        |                 |                                     |

<div style=\"page-break-after: always\"></div>

| II/0019             | B.I.a.1.g - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is not supported by an ASMF and requires significant update to the relevant AS section in the dossier   | 15/12/2022   | 29/06/2023   | Annex II    |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|-----------------------------------|
| PSUSA/10829 /202204 | Periodic Safety Update EU Single assessment - brolucizumab                                                                                                                                                                                                     | 27/10/2022   | n/a          |             | PRAC Recommendation - maintenance |
| IB/0017             | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                   | 16/08/2022   | n/a          |             |                                   |
| IA/0016             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                   | 04/07/2022   | n/a          |             |                                   |
| IG/1521             | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                             | 23/06/2022   | n/a          |             |                                   |
| IB/0013             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                         | 24/05/2022   | n/a          |             |                                   |
| PSUSA/10829 /202110 | Periodic Safety Update EU Single assessment - brolucizumab                                                                                                                                                                                                     | 05/05/2022   | n/a          |             | PRAC Recommendation - maintenance |
| II/0010             | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                 | 24/02/2022   | 28/03/2022   | SmPC and PL |                                   |

<div style=\"page-break-after: always\"></div>

| II/0008   | Update of Section 4.4 of the SmPC with a subsection on intraocular inflammation and update of the warning on intraocular inflammation including retinal vasculitis and/or retinal vascular occlusion, and update of Section 4.8 of the SmPC to update the frequency of the ADRs 'Retinal vasculitis' and 'Retinal vascular occlusion' to 'uncommon'; to merge 'Retinal artery occlusion' and 'retinal vascular occlusion' into 'retinal vascular occlusion'; and to update the description of immunogenicity. All of this is based on the final results of 2 retrospective real world studies that evaluated patients with nAMD for up to 6 months after initiating treatment with brolucizumab and a mechanistic study BASICHR0049 that identified an immune cause of intraocular inflammation including retinal vasculitis and retinal vascular occlusion. The Package Leaflet is updated accordingly. The updated RMP version 7.0 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to   | 14/10/2021   | 18/11/2021   | SmPC and PL   | A higher number of intraocular inflammation events were observed among patients with treatment-emergent antibodies. After investigation, retinal vasculitis and/or retinal vascular occlusion were found to be immune mediated events. Intraocular inflammation, including retinal vasculitis and/or retinal vascular occlusion, may occur following the first intravitreal injection and at any time of treatment. These events were observed more frequently at the beginning of the treatment. Based on clinical studies, these events were more frequent in female patients treated with Beovu than male patients (e.g. 5.3% females vs. 3.2% males in HAWK and HARRIER) and in Japanese patients. Patients treated with Beovu with a medical history of intraocular inflammation and/or retinal vascular occlusion (within 12 months prior to the first brolucizumab injection) should be closely monitored, since they are at increased risk of developing retinal vasculitis and/or retinal vascular occlusion. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0006   | Update of section 4.2 of the SmPC to update the wording of the posology, following the assessment of procedure EMEA/H/C/004913/II/0002. In addition, section 4.4 of the SmPC is updated to inform that the interval between two Beovu doses during maintenance treatment should not be less than every 8 weeks as warranted and the Package Leaflet is updated accordingly. Furthermore, the marketing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 14/10/2021   | 18/11/2021   | SmPC and PL   | The interval between two Beovu doses during maintenance treatment should not be less than 8 weeks considering that a higher incidence of intraocular inflammation (including retinal vasculitis) and retinal vascular occlusion was reported in patients with nAMD who received Beovu every 4 week maintenance dosing in a clinical study compared to patients who received Beovu every 8 or 12 week maintenance dosing in the pivotal Phase III clinical studies.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                     | authorisation holder has taken the opportunity to implement minor editorial changes in section 6.5 of the SmPC. Furthermore, the CHMP considers that this variation implements changes to the decision granting the marketing authorisation due to a significant public health concern. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |          | For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|---------------------------------------------------------------------------------|
| PSUSA/10829 /202104 | Periodic Safety Update EU Single assessment - brolucizumab                                                                                                                                                                                                                                                                                                                                                  | 28/10/2021 | n/a        |          | PRAC Recommendation - maintenance                                               |
| N/0011              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                            | 29/09/2021 | 18/11/2021 | PL       |                                                                                 |
| PSUSA/10829 /202010 | Periodic Safety Update EU Single assessment - brolucizumab                                                                                                                                                                                                                                                                                                                                                  | 06/05/2021 | n/a        |          | PRAC Recommendation - maintenance                                               |
| II/0005/G           | This was an application for a group of variations. In view of the data submitted with the group of variations, amendments to Annex(es) II are recommended. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient     | 14/01/2021 | 19/07/2021 | Annex II |                                                                                 |

<div style=\"page-break-after: always\"></div>

|                     | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits   |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10829 /202004 | Periodic Safety Update EU Single assessment - brolucizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 29/10/2020 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0002             | C.I.4, Update of sections 4. 4, and 4.8 of the SmPC in order to add a new warning on Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                     | 03/09/2020 | 19/07/2021 | SmPC, Labelling and PL | Modifications of the product information: [Section 4.4] Endophthalmitis, intraocular inflammation, traumatic cataract, retinal detachment, retinal vasculitis, and/or retinal vascular occlusion. Addition of: Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of Beovu. In patients developing these events, treatment with Beovu should be discontinued and the events should be promptly managed. [Section 4.8] Addition of: Retinal vascular occlusion, frequency not |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                        |            |            |      | known. Addition of: Retinal vasculitis, frequency not known. For more information, please refer to the Summary of Product Characteristics.   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0004 | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data | 11/08/2020 | n/a        |      |                                                                                                                                              |
| IB/0001 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                              | 11/05/2020 | 19/07/2021 | SmPC |                                                                                                                                              |